01992nam a22002417a 4500 D0001J000168 DOH 20210317092935.0 210317b ||||| |||| 00| 0 eng d Therapeutic value of levocabastine eye drops in the treatment of allergic conjunctivitis, a comparative study versus antazoline-tetrahydrozoline eye drops / Jacinto U. Dy-Liacco [and four others] This double-blind comparative study was done to assess and compare the efficacy and safety of levocabastine eye drops in Filipino patients having allergic conjunctivitis versus those of antazoline-tetrahydrozoline eye drops. A total of 54 children and adult were randomized to receive either levocabastine eye drops 0.5 mg/mL administered twice daily or antazoline (0.5 mg/mL)- tetrahydrozoline (0.4 mg/mL) administered four times a day with a treatment duration of two weeks. The patients were classified, depending on the severity of the signs and symptoms of their allergic conjunctivitis, into three categories namely: mild, moderate, and severe. Global evaluation of treatment was rated as excellent, good, moderate or unsatisfactory. Overall therapeutic response was found to be comparable for the two treatment groups. There were also no significant differences between the adverse reactions arising from both drugs. In conclusion, levocabastine is as safe and effective as antazoline-tetrahydrozoline for the treatment of allergic conjunctivitis with its additional advantages of having a faster onset of action and lesser frequency of administration. Acta Medica Philippina,1997 33 ( 3 ) pages 157-164 Lubricant Eye Drops Ophthalmic Solutions Levocabastine Antazoline-tetrahydrozoline Dy-Liacco, Jacinto U. Siong, Ruben Lim B. Eltanal, Ma. Antonette Kabamalan, Ma. Gracia Valencia, Cynthia I. JA 3569 3569 0 0 nlm 0 0 DOHCL DOHCL ElectronicRes 2021-03-17 0 J000168 D0001J000168 2021-03-17 00:00:00 2021-03-17 JA